Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $74.00 (36.56% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Show:
DateFirmActionRatingPrice TargetDetailsShare
9/23/2014Jefferies GroupInitiated CoverageBuy$74.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2014Robert W. BairdInitiated CoverageOutperform$64.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Cowen and CompanyInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Morgan StanleyInitiated CoverageOverweight$81.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Canaccord GenuityInitiated CoverageBuy$85.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014JPMorgan Chase & Co.Initiated CoverageOverweight$66.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 9/23/2012 forward)
Discuss Ultragenyx Pharmaceutical